XBI News 127.95 05/05/2014 05:49:21 SPDR S&P Biotech (XBI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Biotech (XBI) 127.95 $XBI

SPDR S&P Biotech ETF Set to Possibly Pullback After Yesterday's Rally of 1.38%
Comtex SmarTrend(R) - Thu May 01, 4:40PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $126.53 to a high of $132.49. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $129.42 on volume of 850,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Downtrend Call Working As SPDR S&P Biotech ETF Stock Falls 22.9% (XBI)
Comtex SmarTrend(R) - Mon Apr 28, 5:22PM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 months, SPDR S&P Biotech ETF has returned 22.86% as of today's recent price of $123.55.

Shares of XBI Down 21.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:17AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 month, SPDR S&P Biotech ETF has returned 21.15% as of today's recent price of $126.28.

1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...

After Yesterday's Decline of 1.71%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 4:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $119.06 to a high of $127.86. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $123.85 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...

SPDR S&P Biotech ETF Shares Down 18.7% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Fri Apr 11, 11:11AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 1 month, SPDR S&P Biotech ETF has returned 18.71% as of today's recent price of $130.19.

Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.

Inside the Wild Ride of Biotech ETFs - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Apr 11, 9:01AM CDT
Biotech ETFs have been crashing, but have all the funds been performing the same in the space?

After Yesterday's Decline of 6.40%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 5:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $128.38 to a high of $139.22. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $129.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.

SPDR S&P Biotech ETF Down 12.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Fri Apr 04, 9:59AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 12.45% as of today's recent price of $140.22.

SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 3.56% Loss
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $137.59 to a high of $144.94. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $138.06 on volume of 932,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.

3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Sweta Killa - ZACKS - Mon Mar 31, 1:00PM CDT
Expectation for a larger base of insurers under the Obamacare put these healthcare ETFs in focus for the coming weeks.

10.3% Return Seen to Date on SmarTrend SPDR S&P Biotech ETF Call (XBI)
Comtex SmarTrend(R) - Thu Mar 27, 10:05AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 10.29% as of today's recent price of $143.67.

SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Wed Mar 26, 5:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $141.41 to a high of $148.38. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $142.63 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jacobi's Harness Brings AI from Concept to Reality

Updated Category News Views 0

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...

Continue Reading
U.S. Gold Corp. Gears Up for Key October Event

Updated Category News Views 37

Marking Calendars for the Emerging Growth Showdown There's nothing quite like the buzz leading up to an event where you know someone’s either gonna make a splash or barely leave a ripple. U.S. Gold Corp. is drawing some attention ahead of the Emerging Growth Conference on October 29, 2026. This ain't just any corporate dog-and-pony show—it's a chance for the Gold...

Continue Reading
Ellucian's Cloud Hat-Trick: Leading AI in Education

Updated Category News Views 66

Turning the Dial on Cloud Innovation What’s gripping the talk of the town? It's the powerhouse, Ellucian, clinching the 2026 Stratus Award for Cloud Computing in the Education category, marking a third straight victory. It’s a trifecta that signals something big in the world of higher ed tech. But what does it mean for investors and the sector at large? Unpacking the...

Continue Reading
Medefy's New Award Honors Cost-Savvy Consultants

Updated Category News Views 59

Awarding Ingenuity in Healthcare Cost Containment Ditch the chatter, folks. Let’s talk about a little piece of news that just might be the ripple effect the healthcare sector needs right now. Medefy, that cost-containment whiz, has unleashed 'The Curve Bender Award.' Frankly, it's about time someone spotlighted the gritty work of benefits consultants grinding in the...

Continue Reading
Nektar Therapeutics Gears Up for Q3 Financial Reveal

Updated Category News Views 34

Anticipation Builds as Nektar Preps Financial Report Ah, the life of a biotech investor, riding high or gripping the rail as tides turn with every quarterly report. This time, we're turning our gaze to Nektar Therapeutics and their Q3 financial results slated for release on November 12th, just as the market dust starts settling for the day. Now, if you’re wired to...

Continue Reading
Innodata Faces Investigation After Major Stock Drop

Updated Category News Views 26

Rough Waters for Innodata, Stock Takes a Hit The market can be a brutal place when news hits hard, and that's precisely the situation Innodata Inc. (NASDAQ: INOD) found itself in on October 27, 2026. After a promising rally, the company's shares plummeted by over 20% when news broke of a significant workforce reduction overseas. Unpacking the Numbers Behind the Dive The...

Continue Reading
Fashion Sees Quality Trumping Price in Consumer Preferences

Updated Category News Views 22

Consumers Are Shifting Away from Price-First Mindset You could always count on shoppers looking for a bargain, right? Well, hold your horses, 'cause that train's rolling off the tracks. In today's fashion shuffle, good ol' quality and craftsmanship are giving low prices a run for their money. A study spearheaded by Boston Consulting Group (BCG) and Women's Wear Daily...

Continue Reading
Ferrovial's EUR 600M Scrip Dividend: What's Brewing?

Updated Category News Views 68

Understanding Ferrovial's Latest Financial Maneuver Alright, investors, listen up—Ferrovial's just tossed a hefty EUR 600 million scrip dividend onto the table, giving shareholders the choice between cash or shares. Now, if you've been around the block, this sort of move can mean a few things, and it's best not to treat it like coins rattling in a collection plate. This...

Continue Reading
Jennifer Sharp Bolsters Signature Wealth's Greenville Team

Updated Category News Views 51

New Beginnings with Signature Wealth There's a fresh breeze blowing through Signature Wealth's Greenville office, and its name is Jennifer Sharp. Now, if you're meandering through financial landscapes, Sharp is the guide you didn’t know you needed—until now. With nearly 20 years under her belt, she brings a wealth of experience coupled with a knack for handling life's...

Continue Reading
Covalent's Bet on AML Analytics: A Defense Revolution

Updated Category News Views 11

The Big Play: AI Meets Financial Defense You know when a private equity firm swoops in, it's like the cavalry arriving. Covalent Equity Partners just did that for AML Analytics, or AMLA for short. A payday for them, sure, but it's more about amplifying AMLA's already hefty punch against financial crime, using AI to boot. Now, if AI's mentioned, you know someone's getting...

Continue Reading

Top 5 Most Recently Viewed Articles

Defense Metals Welcomes Ali Mahdavi as New SVP for Growth

Updated Category News Views 262

Defense Metals Welcomes Ali Mahdavi as New SVP for Growth Defense Metals Corp. (TSXV: DEFN) is thrilled to announce that Ali Mahdavi has joined as Senior Vice President of Corporate Development. This strategic appointment aims to bolster the Company's leadership team as they work diligently on their Wicheeda Project. Strengthening Leadership for Strategic Growth Mark...

Continue Reading
Insightful Economic Trends Expected by Chapman University 2026

Updated Category News Views 150

Understanding the Chapman University Economic Forecast for 2026 Chapman University has disclosed key insights from its much-anticipated economic forecast for 2026, a resource utilized for nearly five decades by business leaders and policymakers. The report highlights expectations for real GDP growth of approximately 2.0% in 2026, a noticeable increase from the predicted...

Continue Reading
Pyxis Oncology Welcomes New Vice President for Investor Relations

Updated Category News Views 192

Introduction to Alex Kane's Appointment Pyxis Oncology, Inc. (NASDAQ: PYXS), a pioneering clinical-stage firm dedicated to developing antibody-drug conjugates for challenging cancers, has taken a significant step by appointing Alex Kane as their Senior Vice President of Investor Relations and Capital Markets, effective immediately. Alex Kane's Impressive Background...

Continue Reading
CEO Terry Mendez's Vision for Safe Harbor Financial Success

Updated Category News Views 508

Terry Mendez’s Vision for Safe Harbor Financial's Future GOLDEN, Colo. — SHF Holdings, Inc., operating as Safe Harbor Financial (Nasdaq: SHFS), is reaching a pivotal moment in its journey. In a recent announcement, the newly appointed CEO, Terry Mendez, addressed shareholders, sharing his aspirations and strategic focus for the company. As a key player in providing...

Continue Reading
Gentuity's HF-OCT Imaging System Gains FDA Clearance

Updated Category News Views 75

Gentuity's HF-OCT Imaging System Gains FDA Clearance Gentuity, LLC, a leader in innovative intravascular imaging technologies, has recently celebrated a significant triumph with the FDA's approval of its HF-OCT Imaging System. This cutting-edge device is designed for both pre- and post-percutaneous coronary intervention (PCI) imaging, marking it as a groundbreaking tool...

Continue Reading